These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1301588)

  • 1. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
    Jakse G; Hall R; Bono A; Höltl W; Carpentier P; de Pauw M; Sylvester R
    Prog Clin Biol Res; 1992; 378():69-74. PubMed ID: 1301588
    [No Abstract]   [Full Text] [Related]  

  • 2. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group.
    Jakse G
    Prog Clin Biol Res; 1989; 310():187-92. PubMed ID: 2771992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
    Bouffioux C
    Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428
    [No Abstract]   [Full Text] [Related]  

  • 6. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
    Brosman SA
    Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCG for bladder cancer.
    Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
    [No Abstract]   [Full Text] [Related]  

  • 9. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 10. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
    Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
    Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
    Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
    Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
    [No Abstract]   [Full Text] [Related]  

  • 12. BCG vaccine in urinary bladder cancer.
    Brosman SA
    West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
    [No Abstract]   [Full Text] [Related]  

  • 13. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM; van der Meijden AP; Franssen MP
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
    Barreto L; Csizer Z; Sparkes JD
    Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCG in carcinoma in situ and superficial bladder tumors.
    Lamm DL
    Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
    [No Abstract]   [Full Text] [Related]  

  • 16. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
    Aso Y; Akaza H; Kameyama S; Niijima T
    Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of carcinoma in situ of the urinary bladder with BCG].
    Schnyder von Wartensee M; Ackermann D; Studer UE; Zingg EJ
    Helv Chir Acta; 1989 Aug; 56(3):351-4. PubMed ID: 2807965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Topical BCG therapy of in situ cancer of the urinary bladder].
    Mack D; Jakse G
    Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.